Literature DB >> 20109607

Umbilical cord blood transplantation: the first 20 years.

John E Wagner1, Eliane Gluckman.   

Abstract

In October 1988, the world's first umbilical cord blood transplant (UCBT) was performed. Despite considerable skepticism initially by both scientists and clinical specialists in the field, umbilical cord blood (UCB) has now become one of the most commonly used sources of hematopoietic stem cells (HSCs) for allogeneic transplantation. Today, an estimated 600,000 UCB units have been banked and 20,000 UCB units have been distributed worldwide for both adults and children with life-threatening malignant and nonmalignant diseases. During this first generation of UCBT, substantial advances have been made resulting in better outcomes for our patients. UCB serves as an extraordinary example of translational medicine at its best, where clinical problems compel scientists to move basic discoveries into novel therapeutic approaches. This chapter briefly summarizes the highpoints of the history of UCBT with speculations as to what the next generation of research promises to discover. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20109607     DOI: 10.1053/j.seminhematol.2009.10.011

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  26 in total

1.  Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.

Authors:  B L Tang; X Y Zhu; C C Zheng; H L Liu; L Q Geng; X B Wang; K Y Ding; W Yao; J Tong; K D Song; L Zhang; P Qiang; Z M Sun
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

2.  Therapeutic benefit of treatment of stroke with simvastatin and human umbilical cord blood cells: neurogenesis, synaptic plasticity, and axon growth.

Authors:  Xu Cui; Michael Chopp; Amjad Shehadah; Alex Zacharek; Nicole Kuzmin-Nichols; Cyndy Davis Sanberg; Junhao Dai; Chunling Zhang; Yuji Ueno; Cynthia Roberts; Jieli Chen
Journal:  Cell Transplant       Date:  2012-03-08       Impact factor: 4.064

3.  Characterization of a novel umbilical cord lining cell with CD227 positivity and unique pattern of P63 expression and function.

Authors:  Hasan Mahmud Reza; Boon-Yee Ng; Toan Thang Phan; Donald T H Tan; Roger W Beuerman; Leonard Pek-Kiang Ang
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

4.  Effects of obstetric factors and storage temperatures on the yield of endothelial colony forming cells from umbilical cord blood.

Authors:  Kate E Coldwell; Stephanie J Lee; Jennifer Kean; Cheen P Khoo; Grigorios Tsaknakis; Jon Smythe; Suzanne M Watt
Journal:  Angiogenesis       Date:  2011-07-01       Impact factor: 9.596

Review 5.  Concise review: hematopoietic stem cell aging, life span, and transplantation.

Authors:  Gary Van Zant; Ying Liang
Journal:  Stem Cells Transl Med       Date:  2012-09-05       Impact factor: 6.940

6.  US public cord blood banking practices: recruitment, donation, and the timing of consent.

Authors:  Sherri M Broder; Roselle S Ponsaran; Aaron J Goldenberg
Journal:  Transfusion       Date:  2012-07-15       Impact factor: 3.157

7.  Umbilical cord matrix derived mesenchymal stem cells can change the cord blood transplant scenario.

Authors:  Shabari Tipnis; Chandra Viswanathan
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

Review 8.  Notch signaling in hematopoietic cell transplantation and T cell alloimmunity.

Authors:  Christen L Ebens; Ivan Maillard
Journal:  Blood Rev       Date:  2013-08-31       Impact factor: 8.250

Review 9.  Cord blood transplantation for bone marrow failure syndromes: state of art.

Authors:  Simona Pagliuca; Annalisa Ruggeri; Régis Peffault de Latour
Journal:  Stem Cell Investig       Date:  2019-12-05

Review 10.  Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

Authors:  Nishitha Reddy; Katayoun Rezvani; A John Barrett; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.